Article
Identification of the 5-HT1A serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease.
Neurobiology of disease - 1 May 2021
Pereira-Sousa Joana, Ferreira-Lomba Bruna, Bellver-Sanchis Aina, Vilasboas-Campos Daniela, Fernandes Jorge H, Costa Marta D, Varney Mark A, Newman-Tancredi Adrian, Maciel Patrícia, Teixeira-Castro Andreia
Abstract excerpt
Machado-Joseph disease (MJD) or Spinocerebellar ataxia type 3 (SCA3) is a progressive neurodegenerative disorder that affects movement coordination leading to a premature death. Despite several efforts, no disease-modifying treatment is yet available for this disease. Previous studies pinpointed the modulation of serotonergic signaling, through pharmacological inhibition of the serotonin transporter SERT, as a...
Topics
- Animals
- Ataxin-3
- Caenorhabditis elegans
- Caenorhabditis elegans Proteins
- Disease Models, Animal
- Machado-Joseph Disease
- Mutation
- Piperidines
- Protein Aggregation, Pathological
- Pyridines
- Receptor, Serotonin, 5-HT1A
- Serotonin 5-HT1 Receptor Agonists